COVID-19 Vaccination status among Health care workers diagnosed with COVID-19 in a tertiary care institute of Uttarakhand: A Cross-sectional Study
Keywords:COVID-19, Vaccines, COVID-19 Vaccination, Healthcare Workers
Background: Vaccines are considered as the one of the main pillars in halting and ending the presently on-going coronavirus disease (COVID-19 disease) pandemic which has spread globally since it was first detected in Wuhan, China in December 2019. In the absence of specific therapy, infection prevention practices and mass vaccination remains the mainstay in controlling the disease. Objectives: Objective of the study was to assess COVID-19 vaccination status, socio-demographic and clinical profile among healthcare workers diagnosed with COVID-19. Methodology: A cross-sectional survey from 1st March 2021 to 30th June 2021 among healthcare workers who were diagnosed with COVID-19 in a tertiary care institute of Uttarakhand, India was conducted, and universal sampling was used. Institutional Ethics Committee approved this study. Results: Total 662 healthcare workers were diagnosed with COVID-19. 429 (64.8%) of these COVID-19 diagnosed healthcare workers had received either single (129,30%) or both dose (300,70%) of COVID-19 vaccine while remaining 233 (35.2%) belonged to non-vaccinated group. History of exposure to COVID-19 positive patients was higher in vaccinated (66.4%) than in non-vaccinated group (55%) (p = 0.004). Hospitalisation was found to be higher among non-vaccinated (5.6%) than vaccinated group (2.3%) (p = 0.029). Conclusions: This study concludes that being vaccinated against COVID-19 disease provides protection against severe infection and reduces the need for hospitalization.
Novel Coronavirus (2019-nCoV) situation report -1. World Health Organization. 2020 January 21. [Accessed on 15/12/2022]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf
Update on Novel Coronavirus: one positive case reported in Kerala. (2020). [Accessed on 15/12/2022]. Available from: https://pib.gov.in/PressReleaseIframePage.aspx?PRID=1601095.
WHO Director-General’s Opening remarks at the media briefing on COVID-19- 11 March 2020. [Accessed on 15/12/2022]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
Johns Hopkins coronavirus resourcecentre. Johns Hopkins University of Medicine. [Accessed on 15/12/2022]. Available from: https://coronavirus.jhu.edu/map.html.
Ranjan P, Bhattacharya A, Chakrawarty A, Das R, Kumar A, Pandey S et al. Association between self-reported adherence to preventive practices and probability of turning COVID-19 positive: a cross-sectional analytical study. Cureus, 2020; 12(12): e11815.doi: 10.7759/cureus.11815.
Astrazeneca ties with Indian company to produce potential vaccine. [Accessed on 15/12/2022]. Available from: https://www.hindustantimes.com/world-news/biopharma-major-astrazeneca-ties-up-with-indian-institute-to-produce-potential-vaccine/story-UF9yLSQLRQSKX6NNemnFRK.html.
Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised phase 1 trial. Lancet Inf Dis 2021; 21: 637-46.
Serum Institute of India. Covishield ChAdOx1 nCov19 Coronavirus Vaccine (Recombinant). Covid vaccine insert [Accessed on 15/12/2022]. Available from: https://www.seruminstitute.com/product_covishield.php.
Centers for Disease Control and Prevention. CDC. Ensuring COVID-19 Vaccines work. [Accessed on 15/12/2022]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/index.html.
Singh Ak, Phatak SR, Singh R, Bhattcharjee K, Singh NK, Gupta A et al. Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine 2021; 39(44): 6492 – 509.
Gupta N, Kaur H, Yadav P, Mukhopadhyay L, Sahay RR, Kumar A et al. Clinical characterization and Genomic analysis of COVID-19 breakthrough infections during second wave in different states of India.medRxiv. doi: https://doi.org/10.3390/v13091782 .
Sharma P, Mishra S, Basu S, Kumar R, Tanwar N. Breakthrough Infection With Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Delhi: A Single-Institution Study. Cureus 13(10): e19070.
Srinivasan P. 59% of all COVID deaths in Uttarakhand happened in the month of May 2021 [Internet]. 2021. [Updated 2021 June 02; Accessed on 15/12/2022]. Available from: https://en.gaonconnection.com/uttarakhand-covid-deaths-coronavirus-cases-healthcare-second-wave-vaccination/.
Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. [Preprint]. medRxiv. 2021; 1-14. doi: https://doi.org/10.1101/2021.05.22.21257658.
Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 2021; 397 (10292): 2331 – 2333. doi: https://doi.org/10.1016/S0140-6736(21)01290-3
How to Cite
Copyright (c) 2022 Indian Journal of Community Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.